Zeiss reveals Humphrey Field Analyzer II-i with Guided Progression Analysis software

Article

Carl Zeiss Meditec has unveiled the most advanced visual field testing platform available today - the Humphrey Field Analyzer II-i (HFA II-i) with Guided Progression Analysis (GPA) software.

Carl Zeiss Meditec has unveiled the most advanced visual field testing platform available today - the Humphrey Field Analyzer II-i (HFA II-i) with Guided Progression Analysis (GPA) software. The new system has been designed to accurately determine the stage of glaucoma and progression rate.

The GPA programme, which uses Visual Field Index, has been developed based on data from a 15 centre international clinical trial. It allows the platform to automatically summarize a patient's visual field test results, rate of visual field deterioration and therefore risk of future vision loss, which is then printed onto a single page in a simple format.

According to its manufacturers, HFA II-i with the new GPA software helps doctors to ensure that their glaucoma patients receive the best course of treatment and that vision loss is prevented or minimized.

Carl Zeiss Meditec also announced a host of new product and software upgrade launches at this year's ASCRS congress in Chicago, US. Their product portfolio now includes advanced algorithms for the Cirrus HD-OCT and Stratus OCT systems, new OCT software for their Visante OCT platform and an integrated workflow system for ophthalmic surgery (CALLISTO eye).

Related Videos
A screenshot of Dr Filomena Ribeiro, president of the ESCRS
Ramin Tadayoni, MD, speaks with Sheryl Stevenson
Jennifer I. Lim, MD, FARVO, FASRS, Director of Retina Service, University of Illinois at Chicago
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center
Carl D. Regillo, MD, FACS, FASRS, Chief of Retina Service, Wills Eye Hospital, Philadelphia, PA
Arshad Khanani, MD, MA FASRS, on a virtual call
Penny A Asbell, MD, FACS speaks at the 2023 AAO meeting
© 2024 MJH Life Sciences

All rights reserved.